Aromasin

Exemestane is a steroidal, irreversible aromatase inhibitor developed by Pfizer (originally Pharmacia & Upjohn) for the treatment of advanced breast cancer. Unlike Anastrozole and Letrozole, which reversibly bind to and inhibit the aromatase enzyme, Exemestane is a "suicidal" (mechanism-based) inhibitor: it permanently binds to the aromatase enzyme and deactivates it. New aromatase enzyme must be synthesized by the body to restore activity, a process that takes approximately 2–3 days per turnover cycle.

This suicidal mechanism provides a distinct pharmacological advantage. Because the inhibition is irreversible, estrogen suppression does not depend on maintaining a steady-state blood concentration of the inhibitor. Even as Exemestane is metabolized and cleared, the aromatase enzymes it has already bound remain permanently inactivated. This creates a more durable suppression profile and makes Aromasin less susceptible to "estrogen rebound" — the rapid surge in estradiol that can occur when competitive inhibitors like Anastrozole or Letrozole are abruptly discontinued.

Aromasin suppresses total-body aromatization by approximately 85–95% at the 25 mg daily dose used in clinical oncology. In anabolic research applications, much lower doses are typically sufficient — 12.5 mg every other day is the most common protocol. A notable secondary benefit: Exemestane has been shown in clinical studies to have a mildly positive effect on bone mineral density (unlike competitive AIs, which can reduce bone density) and to have a less detrimental impact on lipid profiles compared to Anastrozole. Some evidence also suggests a modest increase in IGF-1 levels during Exemestane administration.

Aromasin is the preferred AI for researchers who prioritize stable estrogen management and want to minimize the risk of post-AI estrogen rebound. It is particularly well-suited for long cycles, cruise/blast protocols where transitions between aromatizing and non-aromatizing compounds occur, and for researchers who have experienced joint pain or mood disturbance from competitive AIs. It integrates well into PCT bridges because its lipid profile is more favorable.

Exemestane has a half-life of approximately 24 hours. It is fat-soluble and should be administered with a meal containing dietary fat to maximize absorption (bioavailability increases by approximately 40% when taken with food). Standard research dosages are 12.5–25 mg every other day or every third day, titrated to bloodwork. Because it is steroidal in structure, Exemestane does not carry significant hepatotoxicity. The primary risk of over-dosing is the same as any AI: crashed estrogen, presenting as dry joints, lethargy, loss of libido, and mood disturbance. Bloodwork is essential for calibration.